RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Anti-infective biotechnology company Cempra Pharmaceuticals announced today that it has added Aisling Capital as an investor, bringing its Series A financing to a close at $22 million.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Anti-infective biotechnology company Cempra Pharmaceuticals announced today that it has added Aisling Capital as an investor, bringing its Series A financing to a close at $22 million.
